

Requirements for the functional expression of OX40 ligand on human activated CD4⁺ and CD8⁺ T cells

Running title: Functional OX40L on human T cells

Kayo Kondo^a, Kazu Okuma^a, Reiko Tanaka^a, Li Feng Zhang^a, Akira Kodama^a, Yoshiaki Takahashi^b,
Naoki Yamamoto^b, Aftab A. Ansari^c, and Yuetsu Tanaka^a

^a) Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

^b) AIDS research center, National Institute of Infectious Diseases, Tokyo, Japan

^c) Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

Correspondence to: Prof. Y. Tanaka, Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Uehara 207, Nishihara-cho, Nakagami-gun, Okinawa 903-0215, Japan.

Tel: +81-98-895-1202; Fax: +81-98-895-1437

e-mail: yuetsu@s4.dion.ne.jp

Abbreviations used: OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; APCs, antigen-presenting cells; mAb, monoclonal antibody; FCM, flow cytometry; TCR, T cell receptor; TGF, transforming growth factor

KEY WORDS: human OX40L, OX40, T cells, TCR stimulation, TGF- β 1, IL-12, IL-4

ABSTRACT

Interaction between OX40 expressed on activated T cells and its ligand (OX40L) on antigen presenting cells (APC) provides a co-stimulatory signal for T cells to promote acquired immunity. In the present study, we have examined various culture conditions for optimum OX40L expression on T cells stimulated with immobilized anti-CD3/CD28 monoclonal antibodies (mAbs). While the day 3 primed T cells expressed minimal OX40L, after repeated stimulations both the CD4⁺ and CD8⁺ T cells became OX40L-positive as determined by flow cytometry. IL-12 interfered with the OX40L expression. Among activated T cells, a higher frequency of CD8⁺ T cells expressed OX40L than CD4⁺ T cells. By blocking OX40L-OX40 interaction by an anti-OX40 mAb, the number of OX40L⁺ T cells significantly increased. Screening of various cytokines showed that TGF-β1 was capable of induction of OX40L on the activated T cells within 3 days. The OX40L expressed on T cells was functional, as they bound soluble OX40 and stimulated HIV-1 production from HIV-1-chronically infected cell lines expressing OX40. Altogether, the present study indicates that functional OX40L is inducible on human activated CD4⁺ and CD8⁺ T cells, and that the expression is enhanced by TGF-β1.

(191words)

INTRODUCTION

OX40/OX40L (CD134/CD252) represent a growing number of pairs of co-stimulatory molecules and ligands which have been reported to be critical for T cell proliferation, survival, cytokine production and the generation of memory T cells [1-5]. The OX40/OX40L are members of the tumor necrosis factor receptor (TNFR)–TNF super-family with OX40 being transiently expressed primarily by activated T cells following ligation of the T cell receptor (TCR). Its cognate ligand OX40L (also termed gp34) [6, 7] has a broad tissue distribution which includes dendritic cells, Langerhans cells, B cells, natural killer cells, vascular endothelial cells and mast cells, and is not normally detectable on resting cells, but can be up-regulated following activation [8-23]. The patho-physiological relevance of such broad tissue distribution of OX40L requires further study. The interaction between OX40 and OX40L has been described as being highly plastic, a characteristic of the TNFR–TNF super-family which was recently confirmed by the delineation of the crystal structure of the OX40/OX40L complex [24].

While initially the expression of OX40L was thought to be restricted to non-T cells, recent studies appear to question this view. Thus, it has been shown that OX40L is in fact inducible on long-term cultured human CD4⁺ and CD8⁺ cytotoxic T cell lines in addition to T cell lines transformed by human T cell leukemia virus type-I (HTLV-I) [16, 25, 26]. In the murine system, it has been reported that functional OX40L can be induced on TCR-transgenic T cells when they are stimulated *in vitro* [27, 28]. More recently the data from Soroosh et al [29] suggested that indeed OX40L expressed by murine T cells participates in a unique T-T cell signaling system by interaction with OX40 and that such interactions are critical for long-term survival of such T cells. While these studies have been performed using murine T cells, a role for such T-T cell interaction and the optimum conditions and requirements for OX40L expression by human T cells have yet to be defined. Thus, the present studies were conducted to first define the culture conditions which promote OX40L expression by human T cells *in vitro*. We show herein that activated human CD4⁺ and CD8⁺ T cells both can express functional OX40L *in vitro* specially following repeated stimulation, and that TGF- β 1 is a strong inducer of OX40L. The role of OX40L expressed by T cells is discussed.

MATERIALS AND METHODS

Reagents

Medium used was RPMI-1640 medium (Sigma, St. Louis, MO.) supplemented with 5% heat-inactivated fetal calf serum (FCS) (Sigma) (referred to as RPMI medium). No antibiotics were added. Recombinant human IL-2 (rIL-2) was provided courtesy of the US NIH AIDS Research and Reference Reagent Program. The recombinant cytokines rIL-12, rIL-4, rIL-10, rIL-17, rIL-18 rIFN- γ and rTGF- β 1 were purchased from Peprotec (London, UK). The fluorescent mAbs specific for human CD4 and CD8 (PE or PC5-labeled) and Streptavidin-PE were purchased from Beckman-Coulter (CA, USA). The mAbs produced in our laboratory included mouse IgG1 anti-OX40L (clone 5A8) [30], rat IgG2b anti-HCV (clone Mo-8) [31], mouse IgG1 anti-human OX40 (clone B-7B5) [32], rat IgG2b anti-OX40 (clone W4-54 which was generated from a WKA rat and capable of blocking OX40/OX40L interaction), control mouse IgG1 mAb TAXY-8 anti-HTLV-I tax antigen [33]. The mAbs from clones B-7B5 and W4-54 recognized different epitopes of OX40 and did not interfere with each other in terms of binding to the same molecule (unpublished). These in-house mAbs were purified from SCID mouse ascites fluids by gel filtration using Superdex G-200 (Amersham Bioscience, Uppsala, Sweden). These mAbs were labeled using FITC- or Cy5-labeling kits (Dojin, Tokyo, Japan or Amersham) according to the manufacture's instructions. Human T cell negative isolation kit, magnetic beads conjugated with anti-human CD3 and anti-human CD28 mAbs, and magnetic beads conjugated with anti-human CD4 or CD8 were all purchased from Dynal Corp (NY, USA). Biotinylated recombinant soluble human OX40 (sOX40, CD134-muIgG2a/biotin fusion protein) and OX40L (sOX40L, CD134L-muCD8/biotin) were purchased from Ancell (MN, USA). A control for mouse IgG2a was purchased from Ancell. Neutralizing mAbs specific for human TNF- α and TNF- β were purchased from R&D (MN, USA). Anti-CD28 mAb with stimulating activity was purchased from R&D (USA).

Cell Lines

A HIV-1-chronically infected ACH-2 cell line expressing OX40 was derived by OX40-gene transfection as described previously [32]. Other OX40-, OX40L- and control-gene transfected cell lines used in the present study were generated from the human T cell line Molt-4 expressing human CCR5 (kindly provided by Dr. M. Baba of Kagoshima University, Japan), and the human promonocytic cell line U1 which was derived from the HIV-1 chronically-infected U937 cell line. These cell lines were transfected by electroporation using 10-15 μ g of the individual plasmid, as described previously [32]. For the selection of transfectants, 1 μ g/ml puromycin was added to the culture media. The expression of the OX40L or OX40 protein on the cell surface of the transfected cells was confirmed by an

immuofluorescence followed by flow cytometric analysis.

Stimulation of T Cells *in vitro*

Human peripheral blood mononuclear cells (PBMCs) were isolated from heparinized (5 U/ml) blood of normal healthy donors using standard density gradient centrifugation with the use of the human lymphocyte separation medium (Sigma). The cells at the interface were collected and washed three times in cold phosphate-buffered saline (PBS) containing 0.1% BSA (BSA-PBS). PBMCs were re-suspended at 1×10^6 cells/ml in RPMI medium supplemented with 20 U/ml IL-2. Then, 1 ml of the cell suspension was dispensed into individual wells of 12-well plates (B-D, NJ, USA) and mixed with the anti-CD3/CD28 magnetic beads (anti-CD3/28 immunobeads) at a cell to bead ratio of 1:1, and cultured either in the presence or absence of exogenous IL-12, IL-4 or other recombinant cytokines at 20 ng/ml for 3 days at 37°C in a 5% CO₂ humidified incubator. In some experiments, PBMCs were stimulated by plate bound OKT-3 (0.05, 0.5 or 5 µg/ml) and soluble anti-CD28 mAb (1 µg/ml). In addition, for some experiments, T cells were purified using a human CD3⁺ T cell negative isolation kit. Viable cell numbers were assessed on an aliquot of such cells utilizing staining with 0.1% eosin-Y in PBS. After 3 days, activated cells were harvested, adjusted to 2×10^5 cells/ml and further stimulated using the same conditions every 3 days. The anti-OX40 blocking mAb (W4-54) or control mAb (Mo-8) was added to T cell-stimulation cultures at 5 µg/ml.

Flow Cytometry (FCM)

Cells to be analyzed were incubated in a FACS buffer (PBS containing 0.1% NaN₃ and 2% FCS) containing 2 mg/ml human IgG on ice for 15 minutes for the blocking of Fc receptors. Without washing, the cells were then subjected to staining with a set of dye-conjugated mAbs, 5A8-FITC and B-7B5-Cy5, with either anti-CD4-PE or anti-CD8-PE on ice for 30 minutes. Then after washing with FACS buffer, cells were fixed in 1% PFA-containing FACS buffer and analyzed using FACSCalibur, and data obtained were analyzed using Cell Quest software (BD). In order to determine whether activated T cells can bind OX40L and OX40, Fc-blocked cells were incubated with biotinylated sOX40 or sOX40L at 2.5 µg/ml together with either anti-CD4-PC5 or CD8-PC5 for 30 minutes on ice followed by staining with PE-labeled streptavidin (Beckman Coulter) for 30 minutes on ice. After washing with FACS buffer, cells were fixed in 1% PFA-containing FACS buffer and analyzed. In the experiments that were conducted to demonstrate the ability of W4-54 mAb to block the transfer of OX40 to OX40L and vice versa, aliquots of the Molt4/OX40L cells were mixed with Molt4/OX40 cells in the presence of 5 µg/ml W4-54 or control rat IgG for 30 minutes on ice. These cell aliquots were then incubated with pre-determined

optimum concentrations of the 5A8-FITC and B-7B5-Cy5 mAb and subjected to flow cytometric analysis.

OX40 Stimulation Assay

Two HIV-1-chronically infected cell lines (ACH-2 and U1) that had been transfected with human OX40 gene, (ACH-2/OX40 and U1/OX40) ([32], and Takahashi et al., unpublished) were suspended at 2×10^5 cells/ml and co-cultured with equal number of previously activated T cells in a volume of 0.5 ml in a 48-well plate (BD) in RPMI medium for 24-48 hours at 37°C in a 5% CO₂ humidified incubator. To neutralize endogenous TNF, anti-human TNF- α and TNF- β mAbs (at 5 μ g/ml each) were included to block the potential effects of these cytokines synthesized endogenously. HIV-1 replication was determined by quantification of HIV-1 core p24 antigen in the supernatant fluid from such cultures utilizing commercial ELISA kits (Retro-Tec, NY, USA).

RESULTS

Induction of OX40L on Human T cells by Repeated Stimulation.

Results from a series of preliminary studies carried out confirmed previous observations that the expression of both OX40L and OX40 were undetectable on resting T cells isolated from fresh human PBMCs from a number of normal donors as determined by standard FCM (data not shown). In efforts to examine the expression of OX40L and OX40 on activated human T cells, PBMCs were incubated *in vitro* with anti-CD3/28 immunobeads. Pre-determined optimum concentrations of IL-2 and either IL-12 or IL-4 were added to the cultures to generate prototype Th1 or Th2-like populations of human CD4⁺ and CD8⁺ T cells in efforts to examine them for the expression of OX40L and OX40. After 3 days in such culture conditions, the cultures were harvested and the expression of OX40L and OX40 by the CD4⁺ and CD8⁺ T cells was examined by a triple-color staining method. As seen in Fig.1, while >75% of the CD4⁺ T cells and 16-30% of the CD8⁺ T cells expressed cell surface OX40, < 1.5 % of these cells expressed OX40L irrespective of the Th1 or Th2-inducing culture conditions. In efforts to determine if repeated stimulation would facilitate OX40L expression, similar cultures were set up except fresh anti-CD3/28 immunobeads and the same cytokine mixtures were added on days 3 and 6, and the cultures harvested on day 9. Such repeated stimulation had interesting results. Thus, while IL-12 had a modest effect on OX40L expression by CD4⁺ T cells (an increase from 1.4 to 17.3%) most of which co-expressed OX40, similar cultures incubated in IL-4 led to a dramatic increase (from 1.3 to 58.0%) in the frequency of CD4⁺ T cells that co-expressed OX40 and OX40L. On the other hand, while similar repeated stimulation in the presence of IL-12 gave similar effects on the co-expression of OX40L by CD8⁺OX40⁺ T cells (an increase from 1 % to 14.6%) as CD4⁺ T cells, stimulation in the presence of IL-4 not only led to an increase in OX40⁺OX40L⁺ (double positive (DP)) cells (from 0.6% to 36.2%) but also a discrete population of CD8⁺ T cells that expressed only OX40L (0.1% to 45.7%). Repeated studies performed on different days using similar culture conditions showed some degree of variability in the levels of OX40L expression depending upon the donor of the PBMCs (data not shown). However, the basic trend was the same in that whereas the inclusion of IL-12 always led to a modest increase in the frequency of OX40⁺OX40L⁺ (DP) cells within both the CD4⁺ and the CD8⁺ T cell populations upon repeated stimulation, the inclusion of IL-4 consistently led to an increase exclusively in OX40⁺OX40L⁺ (DP) cells within the CD4⁺ T cell population and both OX40⁺OX40L⁺ (DP) and single OX40L⁺ (SP) cells in the CD8⁺ T cell population (Fig.1 and data not shown). Since previous reports utilizing T cells from TCR transgenic mice suggested that weak TCR stimulation is more critical for OX40L expression [34], microtiter plates were coated with the OKT-3 mAb at 5, 0.5 and 0.05 µg/ml for 1 hours at 37°C, and then triplicate wells were cultured with human PBMCs for 3 days. Analyses of activated T cells from these cultures, however, failed to show any

detectable changes in OX40L expression by T cells (data not shown), indicating that differences exist between murine TCR transgenic cells and human bulk T cells in terms of signals required for OX40L expression.

sOX40 Binding by T cells.

In order to examine whether the OX40L molecules expressed by these activated human T cells were functional, we examined the capacity of the repeatedly activated T cells to bind sOX40 by FCM. Fig.2 shows that while sOX40 binds preferentially to the re-stimulated CD8⁺ T cells but not CD4⁺ T cells, sOX40L binds preferentially to the re-stimulated CD4⁺ T cells but not CD8⁺ T cells. In addition, while a markedly higher frequency of the IL-4-treated CD8⁺ T cells bound sOX40 than the IL-12-treated CD8⁺ T cells, sOX40L bound preferentially to the re-stimulated CD4⁺ T cells cultured in IL-12 as compared with IL-4. These data suggest that the induced OX40L molecules were functional in terms of their ability to bind OX40, and that the patterns of the expression of functional OX40L and OX40 by activated T cells differed depending on activation conditions and whether the T cells were of the CD4⁺ or CD8⁺ phenotypes.

Effect of Anti-OX40 Blocking mAb on OX40L Expression

It has previously been shown in the murine system that OX40L expression on activated T cells is down-regulated by cell to cell contact when co-cultured with OX40-expressing cells [29]. In addition, we have shown that human OX40L as well as OX40 molecules can be inter-cellularly transferred, indicating that co-expression of OX40L and OX40 by a single cell or co-cultures of cells individually expressing OX40L and OX40 in the same culture may interfere with OX40L expression and/or detection. In efforts to study OX40L expression without the involvement of interactions between these 2 molecules, a series of mAb specific for OX40 were first screened for their individual ability to block such interactions between OX40 and OX40L. A mAb clone W4-54 was thus identified that was capable of inhibiting the binding of sOX40L to membrane bound OX40. In addition, the effect of the addition of W4-54 on the binding of sOX40 to its cognate ligand OX40L was also studied. We initially utilized the OX40- and OX40L-transfected Molt4 cell line for these studies in efforts to restrict the analysis to a study between these 2 molecules and avoid the potential role of other cell surface molecules expressed by mixed cell populations in primary cultures. Fig.3 demonstrates the data obtained. Thus, as seen in Fig. 3a the addition of the W4-54 mAb completely blocked the ability of sOX40L to bind to the Molt4 cell membrane-expressed OX40 (top panel). Similarly, the addition of the same W4-54 mAb markedly decreased the binding of sOX40 to the Molt4 membrane bound OX40L (bottom panel). The partial

blocking in this latter case may be due to differences in the affinity of the mAb to bind to the sOX40 and the affinity of sOX40 to bind to the Molt4 membrane expressed OX40L. The ability of the W4-54 mAb to inhibit interaction between OX40 and OX40L is further exemplified by the data shown in Fig. 3b. Thus, when the OX40 transfected Molt4 cells were co-cultured with the OX40L-transfected Molt4 cells and the mixed cells analyzed for OX40 and OX40L expression in the presence of the control antibody, there was significant interaction between these transfected cells (bottom left panel). However, the addition of the W4-54 mAb to the mixture of the transfected cells completely inhibited such interaction as seen with the staining profile (bottom right panel). The top left and right panels depict the control profiles in which the OX40- and OX40L-transfected Molt4 cells were mixed with mock-transfected Molt4 cells. In efforts to determine the physiological relevance of these findings, cultures of primary T cells were similarly examined for the expression of OX40L and OX40 following *in vitro* culture in media containing either IL-12 or IL-4 in the presence of either the same blocking W4-54 antibody and control Mo-8 mAb.

Addition of this blocking anti-OX40 mAb to the T cell cultures stimulated by anti-CD3/28 (as described under Fig.1) did not show any significant increase in the OX40L expression after the first stimulation (Fig.4, top panel), indicating that the numbers of OX40L molecules on the T cells were few at early stage of stimulation. But after third stimulation, the antibody treatment showed a marked increase in the frequency of OX40L⁺ cells in both CD4⁺ and CD8⁺ T cell subpopulations treated with IL-12 (Fig.4, bottom panel), indicating that the OX40L molecules detected on the activated human T cells were endogenously synthesized but not transferred from other cells. In addition, these data highlight the problems associated with the analysis of OX40 and OX40L expression on such cultured cells if performed without preventing the interactions between these 2 molecules either by direct cell to cell interaction or by the transfer of soluble forms of such molecules.

The Effect of TGF- β 1

We screened a number of recombinant human cytokines in combination with IL-2 that might influence the expression of OX40L by activated T cells. As shown in Fig.5, among the cytokines tested, only TGF- β 1 showed a low (by CD4⁺ T cells) to modest (by CD8⁺ T cells) enhancement in the induction of OX40L on the activated T cells following as little as 3 days in culture *in vitro*. The cytokines that failed to induce OX40L included IL-10, IL-13, IL-17, IL-18, IFN- γ and IFN- β (Fig.5, and unpublished data), which was not secondary to the dose of the cytokine utilized. Of interest is also to note that IL-12 and IL-13 also increased the frequency of CD8⁺ T cells that express OX40. Studies carried out on primary cultures of PBMCs from another donor incubated *in vitro* in media containing TGF- β 1 for 3 days showed that TGF- β 1 influenced the expression of OX40L by a higher frequency of the CD8⁺ T cell population

than the CD4⁺ T cell population (see Fig. 6a). In addition, there was a distinct population of CD8⁺ T cells that only expressed OX40L but not OX40. In efforts to determine if the TGF- β 1-induced OX40L was functional, aliquots of the TGF- β 1-induced PBMCs were incubated with biotinylated sOX40 or biotinylated sOX40L followed with streptavidin-PE. As seen in Fig. 6b, OX40L expressed by the TGF- β 1-treated CD4⁺ and CD8⁺ T cells was quite functional (giving values of 24.3%- and 61.7%-positive, respectively). However, TGF- β 1 treatment in fact rendered the OX40 molecules non-functional as shown by a reduction of percentages of CD4⁺ T cells bound by sOX40L from 33.2 to 3.4%. In order to exclude the possibility that the OX40L was passively acquired and synthesized by non-T cells in PBMCs, we stimulated purified CD3⁺ T cells in the presence of both TGF- β 1 and anti-OX40 blocking mAb (W4-54), and confirmed that TGF- β 1 indeed induced the endogenous expression of OX40L on both the CD4⁺ and CD8⁺ T cells as early as 12 hours (data not shown).

Cell Stimulating Function of OX40L Expressed on T cells.

Finally, in order to confirm that the OX40L induced on the activated human T cells are biologically functional (in addition to their potential to bind their cognate ligand), we tested whether these OX40L⁺ T cells could stimulate HIV-1 production from HIV-1-chronically infected T cell (ACH-2) and the monocytic cell lines (U1) expressing OX40. Activation by the intracellular NF- κ B pathway has been shown to be the pathway by which OX40 stimulation induces HIV-1 replication in such cells [32]. Fig.7 shows that human bulk T cells repeatedly stimulated in the presence of anti-CD3/CD28 immunobeads and IL-4 as well as those stimulated once in the presence of the immunobeads and TGF- β 1 could stimulate HIV-1 replication in the OX40-expressing T and monocytic cell lines (Fig.7 a and b, respectively). It is apparent that the cell activation which resulted in HIV-1 replication was mediated by OX40 stimulation by OX40L expressed on the T cells since this induction of HIV-1 was significantly inhibited by the addition of anti-OX40L blocking mAb (clone 5A8).

Altogether, the present data indicate that functional OX40L is inducible on both CD4⁺ and CD8⁺ *in vitro* activated human T cells which is dependent on not only the degree of cell activation but also on the culture environment.

DISCUSSION

The data shown herein support the previous findings made by Takasawa et al. [25], who showed that long-term cultured cytotoxic CD4⁺ and CD8⁺ T cell clones express OX40L after stimulation *in vitro*. The data reported herein extend these previous findings and describe new culture conditions that lead to the induction of OX40L on human CD4⁺ and CD8⁺ T cells. Importantly, we demonstrated for the first time that the OX40L molecules induced on the T cells were functional, as they were capable of not only binding soluble recombinant OX40 but also stimulating OX40-expressing cells (Figs.2 and 7). Importantly, the OX40L molecules detected on the activated T cells were endogenously synthesized, but not those transferred from other non-T cells [35] as demonstrated by using the anti-OX40 blocking mAb (W4-54) during *in vitro* activation in the cultures. Interestingly, the findings herein also show for the first time that the immune-suppressive cytokine TGF- β 1 accelerated OX40L expression by primary cultures of activated human CD4⁺ and CD8⁺ T cells. The data presented herein also show that the stimulated individual CD4⁺ or CD8⁺ T cell could co-express OX40L along with OX40.

The reason why repeated activation was necessary for high levels of OX40L expression by the human T cells *in vitro* remains to be elucidated. In the murine system, it has been reported that bulk splenic T cells from normal adult mice do not express detectable levels of OX40L after stimulation with anti-CD3 with or without anti-CD28 stimulation either [13]. This is in contrast to the murine TCR-transgenic T cells that express OX40L readily after antigenic stimulation within a few days [27, 29]. Thus, it is likely that the expression of OX40L by bulk T cells, but not single TCR-expressing T cells, is under a tight control during the initial stage of T cell activation in normal mice and humans. Under physiological conditions, OX40L expression by T cells might be programmed to occur at a later stage of immune responses in order to maintain induced effector memory helper T cells [29].

Our present data suggest that the cytokine environment in the cultures, in which T cell stimulation is carried out, significantly affects OX40L expression. We found that IL-12 was inhibitory for the expression of OX40L by T cells (Fig.1, 2). Because the percentages of OX40⁺ T cells were higher in IL-12-treated T cells than those untreated or IL-4-treated, and anti-OX40 blocking mAb reversed the inhibitory effect of IL-12 on OX40L expression (Fig.4), it seems likely that IL-12 reduced the OX40L expression by T cells through enhanced production of functional OX40 molecules. Again, the effect of IL-12 on OX40L expression by human T cells is in contrast to the murine TCR-transgenic T cells. In this mouse system, the T cells preferentially express OX40L when they are stimulated in the presence of IL-12 via the activation of the STAT-4 pathway, and IL-4 severely down-modulates OX40L expression [27, 28]. Also in contrast to human cases, these TCR-transgenic T cells express enhanced levels of OX40 after treatment with IL-4. These discrepancies in OX40L and OX40 induction may be ascribed to species

-specific differences or simply due to a difference in the materials tested, i.e., bulk T cells from normal adults vs. naïve T cells from the TCR-transgenic mice. Experiments using naïve human T cells stimulated in the presence of anti-IL-4 (Th1-rich) or bulk T cells from normal mice may provide clues to such issues.

Even though there are some discrepancies between the human and murine systems, it is now apparent that endogenous OX40L molecules can be expressed on the activated T cells. Thus, functional OX40L molecules expressed at the cell surface may immediately interact with functional OX40 molecules expressed on the same T cell or adjacent T cells. The fate of OX40L on the T cells is unknown, and thus studies are required to address this issue in more detail in the future. It is possible that some human OX40L may be down-modulated via a post-transcriptional and cell to cell contact-dependent mechanisms as the murine T cell cases as shown by Soroosh et al [29]. Our present data indicate that some OX40L and OX40 molecules remained on the T cell surface without being bound by OX40 and OX40 molecules, respectively (Fig.2). In addition, some OX40L molecules on T cells may be transferred to adjacent cells via an OX40-dependent and/or independent manner [35].

The present study also revealed that the patterns of OX40L and OX40 expression were quite different between CD4⁺ and CD8⁺ T cell subpopulations. Thus, while the CD4⁺ T cells tend to preferentially express OX40, the CD8⁺ T cells appear to preferentially express OX40L (Fig.1, and 4). This difference was not merely phenotypic but also functional, because functional OX40L molecules that could bind soluble OX40 were abundant in CD8⁺ T cells and the OX40 molecules expressed by CD4⁺ T cells could bind sOX40L (Fig.2). One possible mechanism for this may be that the molecular ratios of OX40L and OX40 synthesized in these subpopulations are different. This phenotypic difference indicates that a communication between CD4⁺ and CD8⁺ T cells via OX40L-OX40 interaction is also possible. Since the OX40L-OX40 bindings have been shown to mediate cell to cell adhesion, it is highly possible that the OX40L-OX40 interaction may facilitate cross-talk between the two T cell populations after activation. In the murine system, Soroosh et al. [29] hypothesized that OX40L expressed by CD4⁺ T cells can provide autonomous OX40 signals through T cell to T cell interactions which contribute to the longevity of antigen-specific CD4⁺ T cells and thus lead to the generation and survival of CD4⁺ memory T cells. The other functions suggested in the murine system include deviation of a Th1 response to a Th2 response [28], and control of Th2 proliferation [27]. Another possible speculation is that in addition to the immune-stimulating roles, the OX40L/OX40 interaction between activated T-T cells may serve as a feedback mechanism for the regulation of immune responses by rendering the OX40⁺ T cells unresponsive to further OX40L signals from APC following saturation or masking of functional OX40. In addition, interaction of OX40L/OX40 on T-T cells may result in apoptosis of the cells involved in select environments since OX40 signal alone or together with TNF has been shown to enhance apoptosis of

OX40-transfectants [36, our unpublished data]. In addition to the signals generated by OX40 engagement, it is clear that engagement of OX40L also delivers a signal to the APC, which results in increased production of IL-12 by human DCs [10] leading to enhanced murine B cell differentiation [8]. Thus, it is very interesting to examine whether cross-linking of OX40L generates such signals to the T cells. Soroosh et al. [29] mentioned that cross-linking OX40L on T cells with a recombinant soluble OX40 or anti-OX40L mAb did not promote T cell proliferation, but rather suppressed it. Our preliminary experiments also failed to demonstrate any blocking or enhancing effects by anti-OX40L or anti-OX40 mAb on cell proliferation, cytokine production or T cell survival *in vitro* (data not shown).

Finally, although some reagents that trigger human OX40L on a number of non-T cell lineages such as the CD11c⁺ DC [37], NK cells [21] and mast cells [22] have been reported, it should be emphasized that TGF- β 1 played a prominent role in inducing the expression of functional OX40L on both human CD4⁺ and CD8⁺ T cells within 3 days after activation (Figs.5, 6 and 7). Since TGF- β 1 is known to induce IL-17 to generate Th17 cells [38], it is interesting to test whether the OX40L⁺ cells are related to Th17 cells or not. Preliminary data obtained in our laboratory indicated that TGF- β 1 exerted its OX40L-inducing effect on T cells as early as 12 hours after T cell activation even in cultures of T cells that had been previously treated with mitocycin-C (data not shown), suggesting that TGF- β 1 directly stimulates activated T cells to express OX40L without a requirement for either IL-17 or cell proliferation. The biological function of this TGF- β 1-induced OX40L is not known at present. However, it can be speculated that the OX40L/OX40 interaction may be partly involved in multiple functions of TGF- β 1 [39] on immune responses including generation of regulatory T cells [40] and autonomous promoting survival of peripheral T cells [41]. It is interesting to examine whether such OX40L-expressing T cells express Foxp3 or not. However, at present, we are unable to test this due to the fact that our anti-OX40L mAbs used to stain the cells is not detectable on the cell surface following treatment of the OX40L expressing cells with the permeabilization buffer provided with the human Foxp3 staining kit (eBioscience, Inc., San Diego, CA, USA, data not shown). Further studies are in progress to elucidate the precise immunological roles of OX40L expression by human T cells.

ACKNOWLEDGEMENT

We thank NIH AIDS Research and Reference Reagent Program for supplying IL-2. This work was supported by grants from a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; Research on HIV/AIDS and Health Sciences focusing on Drug Innovation from the Ministry of Health, Labor and Welfare of Japan; and Japan Human Science Foundation.

FIGURE LEGENDS

Fig.1. OX40L expression by human activated T cells. PBMCs were stimulated with anti-CD3/CD28 immunobeads in the presence of IL-2 together with either IL-12 (+IL-12) or IL-4 (+IL-4) every 3 days. T cells 3 days after the first stimulation (1st) and third stimulation (3rd) were subjected to a multicolor staining using 5A8-FITC, B-7B5-Cy5 and either CD4-PE or CD8-PE. Flow cytometry data on OX40L and OX40 expression by T cells of CD4⁺ or CD8⁺ gate were shown as dot blots. Numbers in the dot blot graphs indicate percent positive cells. Data shown is representative of 3 similar experiments.

Fig.2. Expression of functional OX40L and OX40 on repeatedly activated T cells. Aliquots of cultures of PBMCs re-stimulated three times every 3 days for a total of 9 days with anti-CD3/28 immunobeads in the presence of IL-2 together with either IL-12 (+IL-12) or IL-4 (+IL-4) were incubated with either biotinylated recombinant soluble forms of OX40 or OX40L along with either CD4-PC5 or CD8-PC5 mAb for gating. Binding of the soluble proteins was detected by using streptavidin-PE. The bars and the numbers displayed in the histogram graphs show positive area and percent positive cells. The control profile used to define the bar for the positive area was obtained on aliquots of the cultured cells untreated with the soluble proteins. Data shown is representative of 3 similar experiments.

Fig.3. Anti-OX40 mAb (W4-54) blocks OX40-OX40L interaction.

(a) Molt4 cells expressing OX40 (Molt4/OX40) or those expressing OX40L (Molt4/OX40L) were pre-incubated with 5 µg/ml W4-54 or negative control mAb (Mo-8) for 30 minutes on ice. These cells were then incubated with biotinylated sOX40L or sOX40 without washing for additional 30 minutes on ice followed by staining with streptavidin-PE. The top and bottom panels depict the sOX40L binding to Molt4/OX40 cells and sOX40 binding to Molt4/OX40L cells, respectively. The thin line represents background staining with streptavidin-PE, and while the dotted line represents staining with sOX40L or sOX40 in the presence of the negative control mAb. The dark thick line represents staining in the presence of the W4-54 blocking antibody. Data shown is representative of 3 similar experiments.

(b) In order to test the ability of W4-54 to prevent OX40 and OX40L transfer by cell to cell contact, Molt4/OX40L cells and Molt4/OX40 cells were each mixed either with the mock-transfected Molt4 cells or mixed with each other in the presence of 5 µg/ml of W4-54 blocking antibody or for purposes of control the Mo-8 mAb on ice for 30 minutes. These mixed population of cells were then stained with anti-OX40L-FITC (5A8) and a different clone of anti-OX40-Cy5 (B-7B5). Representative data from 3 experiments are shown. Note that when Molt4/OX40L cells and Molt4/OX40 cells were co-cultured in the control mAb, the Molt4/OX40 cells acquired OX40L, and at the same time, the Molt4/OX40L cells

acquired OX40 as we showed previously [35].

Fig.4. Effect of anti-OX40 blocking mAb on the expression of OX40L by T cells. PBMCs were stimulated for 3 days (1st stim.) or re-stimulated on days 3 and 6 and harvested on day 9 (3rd stim.) as described in Fig.1 in the presence of either IL-12 or IL-4 and in the presence of either 5 µg/ml W4-54 or the control mAb (Mo-8). The cells were then analyzed for the expression of OX40L and OX40 using 5A8-FITC and B-7B5-Cy5, respectively. Data shown reflects the profile observed on gated populations of CD4-PE- or CD8-PE-positive cells. Data shown is representative of 3 similar experiments.

Fig.5. Effect of various cytokines on the induction of OX40L by primary activated T cells. PBMCs were cultured in vitro for 3 days as described in Fig.1 in the presence of 20 U/ml IL-2 in combination with each of various cytokines at 20 ng/ml. Thereafter, the cells were stained with 5A8-FITC and B-7B5-Cy5 together with either CD4-PE or CD8-PE. The cells were then subjected to flow cytometric analysis and the profile of OX40 or OX40L was determined on CD4- or CD8-gated population of cells. Data shown is representative of 3 similar experiments.

Fig.6. TGF-β1 triggers functional OX40L expression on primary activated T cells. PBMCs from another donor different from one examined in Fig.5 were activated as described in Fig.1 in IL-2 medium either in the presence or absence of 20 ng/ml TGF-β1 for 3 days for 3 days. (a) Expression of OX40L and OX40 was determined by a multicolor staining with mAbs as outlined under Fig.1. (b) Bindings of sOX40 and sOX40L proteins were examined as described under Fig.2. Data shown is representative of 3 similar experiments.

Fig.7. Effect of human T cells stimulated with anti-CD3/CD28 immunobeads either three times or once in the presence of IL-4 or TGF-β1, respectively, on HIV-1 production from HIV-chronically-infected cell lines expressing OX40.

(a) ACH-2 cells expressing OX40 (ACH-2/OX40) were co-cultured for 24 hours with T cells that had been previously stimulated 3-times on days 0, 3 and 6 with anti-CD3/CD28 immunobeads for a total of 9 days in the presence of IL-4 and IL-2. (b) U1 cells expressing OX40 (U1/OX40) were co-cultured for 2 days with PBMCs that had been stimulated with anti-CD3/CD28 immunobeads in the presence of TGF-β1 and IL-2 for 3 days. Because endogenous TNF-α and -β are capable of stimulating these two cell lines leading to HIV-1 production, 5µg/ml anti-TNF-α and -β were included during the culture period. Anti-OX40L mAb (5A8) at 5µg/ml was used to block OX40L-OX40 interactions. The levels of HIV-1

p24 produced in the culture supernatants were determined by ELISA. Controls consisted of the ACH-2/OX40 and the U1/OX40 cells cultured alone (controls), and the ACH-2/OX40 and the U1/OX40 cells treated with anti-OX40L antibody prior to co-culture with the OX40L-expressing activated T cells (act.T + anti-OX40L). Each combination of culture was performed in triplicate and the bars show standard errors. Data shown is representative of 3 similar experiments.

REFERENCES

- (1) Weinberg AD, Vella AT, Croft M: OX-40: life beyond the effector T cell stage. *Semin. Immunol* 10:471, 1998.
- (2) Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-x_L and Bcl-2 expression and is essential for long-term survival of CD4 T cells. *Immunity* 15:445, 2001.
- (3) Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M: The costimulation-regulated duration of PKB activation controls T cell longevity. *Nat Immunol* 5:150, 2004.
- (4) Sugamura, K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. *Nat Rev Immunol* 4:420, 2004.
- (5) Song J, So T, Cheng M, Tang X, Croft M: Sustained surviving expression from OX40 costimulatory signals drives T cell clonal expansion. *Immunity* 22:621, 2005.
- (6) Miura, S., K. Ohtani, N. Numata, M. Niki, K. Ohbo, Y. Ina, T. Gojobori, Y. Tanaka, H. Tozawa, M. Nakamura, and Sugamura K: Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. *Mol Cell Biol* 11:1313, 1991.
- (7) Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG: Identification of a human OX-40 ligand, a costimulator of CD4⁺ T cells with homology to tumor necrosis factor. *J Exp Med* 180:757, 1994.
- (8) Stuber, E., M. Neurath, D. Calderhead, H. P. Fell, W. Strober: Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. *Immunity* 2:507, 1995.
- (9) Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, Imamura S, Uchiyama T: The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. *J Exp Med* 183:2185, 1996.
- (10) Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G: Expression and function of OX40 ligand on human dendritic cells. *J Immunol* 159:3838, 1997.
- (11) Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, Hermann P, Delespesse G: OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4⁺ T cells into high IL-4-producing effectors. *Blood* 92:3338, 1998.
- (12) Pippig SD, Pena-Rossi C, Long J, Godfrey WR, Fowell DJ, Reiner SL, Birkeland ML, Locksley RM, Barclay AN, Killeen N: Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). *J Immunol* 163:6520, 1999.
- (13) Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A, Nohara C, Yagita H, Okumura K: CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. *J Immunol* 162:705866, 1999.
- (14) Weinberg AD, Wegmann KW, Funatake C, Whitham RH: Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. *J Immunol* 162:1818, 1999.
- (15) Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, Greenfield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, Sharpe AH: Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. *Immunity* 11:689, 1999.
- (16) Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, Noda T, Sugamura K: Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. *J Exp Med* 191:365, 2000.
- (17) Wang HC, Klein JR: Multiple levels of activation of murine CD8⁺ intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-, and IL-10 regulation. *J Immunol* 167:6717, 2001.
- (18) Sato T, Ishii N, Murata K, Kikuchi K, Nakagawa S, Ndhlovu LC, Sugamura K: Consequences of OX40-OX40 ligand interactions in Langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice. *Eur J Immunol* 32:3326, 2002.
- (19) Fillatreau S, Gray D: T cell accumulation in B cell follicles is regulated by dendritic cells and is independent of B cell activation. *J Exp Med* 197:195, 2003.
- (20) Ito T, Amakawa R, Inaba M, Hori T, Ota M, Nakamura K, Takebayashi M, Miyaji M, Yoshimura T, Inaba K, Fukuhara S: Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. *J Immunol* 172:4253, 2004.
- (21) Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL: Cross-talk between activated human NK cells and CD4⁺ T cells via OX40-OX40 ligand interactions. *J Immunol* 173:3716, 2004.
- (22) Kashiwakura J, Yokoi H, Saito H, Okayama Y: T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. *J Immunol* 173:5247, 2004.
- (23) Mestas J, Crampton SP, Hori T, Hughes CC: Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. *Int Immunol* 17:737, 2005.
- (24) Compaan DM, Hymowitz SG: The crystal structure of the costimulatory OX40-OX40L complex. *Structure* 14:1321, 2006.
- (25) Takasawa N, Ishii N, Higashimura N, Murata K, Tanaka Y, Nakamura M, Sasaki T, Sugamura K: Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. *Jpn J Cancer Res* 92:377, 2001.
- (26) Tanaka Y, Inoi T, Tozawa H, Yamamoto N, Hinuma Y: A glycoprotein antigen detected with new monoclonal

- antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). *Int J Cancer* 36:549, 1985.
- (27) Kim MY, Bekiraris V, McConnell FM, Gaspal FM, Raykundalia C, Lane PJ: OX40 signals during priming on dendritic cells inhibit CD4 T cell proliferation: IL-4 switches off OX40 signals enabling rapid proliferation of Th2 effectors. *J Immunol* 174:1433, 2005.
 - (28) Mendel I, Shevach EM: Activated T cells express the OX40 ligand: requirements for induction and costimulatory function. *Immunology* 117:196, 2006.
 - (29) Soroosh P, Ine S, Sugamura K, Ishii N: OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. *J Immunol* 176:5975, 2006.
 - (30) Tozawa H, Andoh S, Takayama Y, Tanaka Y, Lee B, Nakamura H, Hayami M, Hinuma Y: Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I). *Int J Cancer* 41:231, 1988.
 - (31) Inudoh M, Kato N, Tanaka Y: New monoclonal antibodies against a recombinant second envelope protein of Hepatitis C virus. *Microbiol Immunol* 42:875, 1998.
 - (32) Takahashi Y, Tanaka Y, Yamashita A, Koyanagi Y, Nakamura M, Yamamoto N: OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. *J Virol* 75:6748, 2001.
 - (33) Tanaka Y, Yoshida A, Tozawa H, Shida H, Nyunoya H, Shimotohno K: Production of a recombinant human T-cell leukemia virus type-1 trans-activator(tax1) antigen and its utilization of monoclonal antibodies against various epitopes on the tax1 antigen. *Int J cancer* 48:623, 1991.
 - (34) Kim MY, Anderson G, White A, Jenkinson E, Arlt W, Martensson IL, Erlandsson L, Lane PJ: OX40 ligand and CD30 ligand are expressed on adult but not neonatal CD4+CD3- inducer cells: evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression. *J Immunol* 174:6686, 2005.
 - (35) Baba E, Takahashi Y, Lichtenfeld J, Tanaka R, Yoshida A, Sugamura K, Yamamoto N, Tanaka Y: Functional CD4 T cells after intercellular molecular transfer of OX40 ligand. *J Immunol* 167:875, 2001.
 - (36) Ma BY, Mikolajczak SA, Danesh A, Hosiawa KA, Cameron CM, Takaori-Kondo A, Uchiyama T, Kelvin DJ, Ochi A: The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. *Blood* 106:2002, 2005.
 - (37) Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, Qin FX, Yao Z, Cao W, Liu YJ: TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. *J Exp Med* 202:1213, 2005.
 - (38) Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. *Nature* 441:231, 2006.
 - (39) Wahl SM, Wen J, Moutsopoulos N: TGF-beta: a mobile purveyor of immune privilege. *Immunol Rev* 213:213, 2006.
 - (40) Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med* 198:1875, 2003.
 - (41) Li MO, Sanjabi S, Flavell RA: Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. *Immunity* 25:455, 2006.





Fig. 3




Fig.4

